vs
Dominari Holdings Inc.（DOMH）与HERON THERAPEUTICS, INC.（HRTX）财务数据对比。点击上方公司名可切换其他公司
HERON THERAPEUTICS, INC.的季度营收约是Dominari Holdings Inc.的1.3倍（$40.6M vs $30.1M），HERON THERAPEUTICS, INC.净利率更高（-7.3% vs -438.1%，领先430.8%），Dominari Holdings Inc.同比增速更快（220.4% vs -0.5%），过去两年Dominari Holdings Inc.的营收复合增速更高（369.1% vs 8.2%）
安提贝制药是一家总部位于多伦多的制药企业，由曾参与创立全球首个气态介质药物开发企业NicOx的约翰·L·华莱士创立于2009年。该企业专注于依托气态介质技术研发缓解疼痛与炎症的药物，2013年在多伦多风险交易所挂牌，2015年收购再生医学领域经销商Citagenix，2020年11月转板多伦多证券交易所。
DOMH vs HRTX — 直观对比
营收规模更大
HRTX
是对方的1.3倍
$30.1M
营收增速更快
DOMH
高出220.9%
-0.5%
净利率更高
HRTX
高出430.8%
-438.1%
两年增速更快
DOMH
近两年复合增速
8.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $30.1M | $40.6M |
| 净利润 | $-131.8M | $-3.0M |
| 毛利率 | — | 72.6% |
| 营业利润率 | -8.9% | 0.1% |
| 净利率 | -438.1% | -7.3% |
| 营收同比 | 220.4% | -0.5% |
| 净利润同比 | -12426.2% | -180.6% |
| 每股收益（稀释后） | $-6.94 | $-0.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DOMHHRTX
| Q4 25 | $30.1M | $40.6M | ||
| Q3 25 | $50.8M | $38.2M | ||
| Q2 25 | $34.1M | $37.2M | ||
| Q1 25 | $8.1M | $38.9M | ||
| Q4 24 | $9.4M | $40.8M | ||
| Q3 24 | $4.0M | $32.8M | ||
| Q2 24 | $6.2M | $36.0M | ||
| Q1 24 | $1.4M | $34.7M |
净利润DOMHHRTX
| Q4 25 | $-131.8M | $-3.0M | ||
| Q3 25 | $125.2M | $-17.5M | ||
| Q2 25 | $16.6M | $-2.4M | ||
| Q1 25 | $-32.5M | $2.6M | ||
| Q4 24 | $1.1M | $3.7M | ||
| Q3 24 | $-4.2M | $-4.8M | ||
| Q2 24 | $-6.1M | $-9.2M | ||
| Q1 24 | $-5.4M | $-3.2M |
毛利率DOMHHRTX
| Q4 25 | — | 72.6% | ||
| Q3 25 | — | 68.8% | ||
| Q2 25 | — | 73.5% | ||
| Q1 25 | — | 78.3% | ||
| Q4 24 | — | 74.9% | ||
| Q3 24 | — | 71.2% | ||
| Q2 24 | — | 70.8% | ||
| Q1 24 | — | 75.6% |
营业利润率DOMHHRTX
| Q4 25 | -8.9% | 0.1% | ||
| Q3 25 | -3.1% | -10.7% | ||
| Q2 25 | -57.0% | -4.4% | ||
| Q1 25 | -394.6% | 8.1% | ||
| Q4 24 | 0.4% | 10.2% | ||
| Q3 24 | -79.1% | -13.6% | ||
| Q2 24 | -44.3% | -17.9% | ||
| Q1 24 | -205.2% | -13.8% |
净利率DOMHHRTX
| Q4 25 | -438.1% | -7.3% | ||
| Q3 25 | 246.4% | -45.8% | ||
| Q2 25 | 48.7% | -6.4% | ||
| Q1 25 | -400.5% | 6.8% | ||
| Q4 24 | 11.4% | 9.0% | ||
| Q3 24 | -104.2% | -14.8% | ||
| Q2 24 | -99.1% | -25.6% | ||
| Q1 24 | -398.0% | -9.1% |
每股收益（稀释后）DOMHHRTX
| Q4 25 | $-6.94 | $-0.01 | ||
| Q3 25 | $7.27 | $-0.10 | ||
| Q2 25 | $1.12 | $-0.02 | ||
| Q1 25 | $-3.02 | $0.01 | ||
| Q4 24 | $0.21 | $0.02 | ||
| Q3 24 | $-0.67 | $-0.03 | ||
| Q2 24 | $-1.01 | $-0.06 | ||
| Q1 24 | $-0.91 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $80.5M | $28.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $69.4M | $14.3M |
| 总资产 | $112.9M | $255.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DOMHHRTX
| Q4 25 | $80.5M | $28.6M | ||
| Q3 25 | $176.2M | $43.1M | ||
| Q2 25 | $28.2M | $16.5M | ||
| Q1 25 | $18.9M | $19.3M | ||
| Q4 24 | $8.2M | $25.8M | ||
| Q3 24 | $7.2M | $25.7M | ||
| Q2 24 | $12.1M | $18.4M | ||
| Q1 24 | $7.1M | $20.4M |
股东权益DOMHHRTX
| Q4 25 | $69.4M | $14.3M | ||
| Q3 25 | $210.2M | $14.9M | ||
| Q2 25 | $88.6M | $-27.3M | ||
| Q1 25 | $42.4M | $-28.5M | ||
| Q4 24 | $39.9M | $-33.7M | ||
| Q3 24 | $38.3M | $-40.0M | ||
| Q2 24 | $42.4M | $-37.9M | ||
| Q1 24 | $47.7M | $-33.8M |
总资产DOMHHRTX
| Q4 25 | $112.9M | $255.9M | ||
| Q3 25 | $223.4M | $248.9M | ||
| Q2 25 | $109.3M | $232.1M | ||
| Q1 25 | $52.3M | $235.8M | ||
| Q4 24 | $47.1M | $233.1M | ||
| Q3 24 | $43.4M | $220.8M | ||
| Q2 24 | $49.1M | $218.1M | ||
| Q1 24 | $52.2M | $217.9M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $22.7M | $-9.2M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流DOMHHRTX
| Q4 25 | $22.7M | $-9.2M | ||
| Q3 25 | $-4.9M | $1.3M | ||
| Q2 25 | $-353.0K | $-10.9M | ||
| Q1 25 | $1.2M | $-8.9M | ||
| Q4 24 | $-16.7M | $-11.8M | ||
| Q3 24 | $-4.7M | $3.4M | ||
| Q2 24 | $1.4M | $-4.6M | ||
| Q1 24 | $-8.6M | $-9.5M |
自由现金流DOMHHRTX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-11.1M | ||
| Q1 25 | — | $-9.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $2.9M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
自由现金流率DOMHHRTX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -29.8% | ||
| Q1 25 | — | -23.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 9.0% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资本支出强度DOMHHRTX
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.6% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金转化率DOMHHRTX
| Q4 25 | — | — | ||
| Q3 25 | -0.04× | — | ||
| Q2 25 | -0.02× | — | ||
| Q1 25 | — | -3.37× | ||
| Q4 24 | -15.65× | -3.22× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DOMH
| Chief Operating Decision Maker | $30.1M | 100% |
| Commissions | $458.0K | 2% |
HRTX
| CINVANTI | $22.9M | 56% |
| ZYNRELEF | $12.5M | 31% |
| Aponvie | $3.8M | 9% |
| SUSTOL | $1.3M | 3% |
